Karessa's first day of trading on First North

Today is the first trading day for Karessa (ticker code KARE) on Nasdaq
Stockholm First North. Karessa is developing and commercialising the next
generation of medicinal products to treat erectile dysfunction. The market is
worth around USD 4.3 billion and is about to undergo significant changes,
opening up major opportunities for Karessa.
Almost half of all men above the age of 40 suffer from some degree of erectile
dysfunction, i.e. the inability to achieve and maintain an erection that is
sufficient to enable sexual activity. Karessa aims to develop the next
generation of products in this field, offering a faster and more reliable effect
than those currently dominating the market.

"The listing is a natural step in our endeavours to build a world-leading
company in the growing market for erectile dysfunction treatments," says
Torbjörn Kemper, CEO of Karessa.

Until very recently, the market has been dominated by three players: Pfizer Inc
(Viagra), Eli Lilly & Co (Cialis) and Bayer AG (Levitra/Staxyn). The patents
behind the drugs supplied by these players are now successively expiring, and in
line with this the market is opening up to new players. In addition to this,
discussions are under way in several countries regarding the possibility of
selling the drugs without prescription, as is already the case in New Zealand.
This would probably further fuel demand.

"Our business model is based on combining proven, effective and approved
substances with our own patented drug-delivery platform," says Kemper. "Through
this combination, we are generating significant benefits, both for the patient
and for Karessa itself. Our medicinal product will not be taken in tablet form,
but will instead be delivered directly into the bloodstream via a film that is
applied discreetly to the oral mucosa. Herein lies the strength and the
uniqueness of our concept."

The main advantages include a faster and more reliable effect compared with
traditional oral tablets. Since the drug is delivered straight into the
bloodstream and does not need to pass the stomach, its uptake is only minimally
affected by simultaneous consumption of food and drink – which can otherwise
make a large difference.

"Erectile dysfunction is a very common condition, and Karessa's solution will
enable a welcome return to spontaneity," says Kemper. "For Karessa's part, the
concept means a shorter time to market, lower costs and significantly reduced
risk with regard to development and clinical studies."

The shortname for the share is KARE and the ISIN code is SE0005506193. Remium is
Certified Advisor for Karessa.
For more information, visit Karessa's new website – www.karessa.se – or contact:
Torbjörn Kemper
CEO
+46 (0) 8-768 22 33
torbjorn.kemper@karessa.se
About Karessa Pharma AB
Karessa Pharma AB is developing and commercialising the next generation of
medicinal products to treat erectile dysfunction. Karessa's concept is based on
a patented drug delivery film, which is combined with clinically tested and
proven active substances. This combination results in a medicinal product that
delivers both a direct and reliable effect. Karessa's shares are traded on
Nasdaq First North. www.karessa.se